Spots Global Cancer Trial Database for nivolumab
Every month we try and update this database with for nivolumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | NCT02982486 | Soft Tissue Sar... Bone Sarcoma Chondrosarcoma Gastrointestina... Ewing's Tumor M... Ewing's Tumor R... Osteosarcoma Desmoplastic Sm... | Ipilimumab Nivolumab | 18 Years - | Assaf-Harofeh Medical Center | |
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | NCT03770299 | Non-Small Cell ... Non-Small-Cell ... Circulating Tum... | Nivolumab Vinorelbine Gemcitabine Docetaxel Pemetrexed Cisplatin Carboplatin Paclitaxel Observation | 18 Years - | Bristol-Myers Squibb | |
| Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | NCT03841201 | Advanced Hepato... | Lenvatinib Nivolumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | NCT03816358 | Pancreatic Aden... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | Anetumab Ravtan... Biopsy Biospecimen Col... Gemcitabine Hyd... Ipilimumab Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | NCT02453620 | Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Invasive Breast... Malignant Solid... | Biopsy Blood Sample Bone Scan Computed Tomogr... Entinostat Ipilimumab Nivolumab Pharmacogenomic... Pharmacological... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas | NCT02451982 | Pancreatic Canc... | Cyclophosphamid... GVAX pancreatic... Nivolumab Urelumab BMS-986253 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | NCT03470922 | Melanoma | Relatlimab Nivolumab | 12 Years - | Bristol-Myers Squibb | |
| Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | NCT03104439 | Microsatellite ... Pancreatic Canc... MSI High Colore... | Nivolumab Ipilimumab Radiation Thera... | 18 Years - | Massachusetts General Hospital | |
| A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | NCT02982486 | Soft Tissue Sar... Bone Sarcoma Chondrosarcoma Gastrointestina... Ewing's Tumor M... Ewing's Tumor R... Osteosarcoma Desmoplastic Sm... | Ipilimumab Nivolumab | 18 Years - | Assaf-Harofeh Medical Center | |
| Neoadjuvant Nivolumab in Glioblastoma | NCT02550249 | Glioblastoma Mu... | Nivolumab | 1 Year - | Clinica Universidad de Navarra, Universidad de Navarra | |
| A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | NCT02423343 | Solid Tumor Non-Small Cell ... Hepatocellular ... | Galunisertib Nivolumab | 18 Years - | Eli Lilly and Company | |
| CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | NCT05257590 | Hepatocellular ... Advanced Cancer | Nivolumab Injec... CVM-1118 | 18 Years - | TaiRx, Inc. | |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | NCT04913922 | Acute Myeloid L... | Azacitidine Inj... Nivolumab Relatlimab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC | NCT05418660 | Non-small Cell ... | Immunotherapy | 18 Years - | University of Milano Bicocca | |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors | NCT04572451 | Melanoma Carcinoma, Rena... Unresectable So... | nivolumab BMS-986253 Stereotactic Bo... | 18 Years - | University of Pittsburgh | |
| An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors | NCT03864575 | Metastatic Canc... | Celecoxib 400 m... | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome | NCT03767439 | Basal Cell Nevu... | Vismodegib Nivolumab Ipilimumab | 18 Years - | Columbia University | |
| ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma | NCT03003637 | Immunotherapy Head and Neck N... | Nivolumab Ipilimumab | 18 Years - | The Netherlands Cancer Institute | |
| Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer | NCT03101566 | Biliary Tract N... | Gemcitabine Cisplatin Ipilimumab Nivolumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. | NCT04229459 | Esophageal Squa... | Cisplatin 5-FU Radiation thera... Cetuximab Nivolumab | 18 Years - | Rabin Medical Center | |
| Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | NCT05498792 | Locally Advance... | CBL0137 Ipilimumab Nivolumab | 18 Years - | Fox Chase Cancer Center | |
| TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer | NCT03287674 | Metastatic Ovar... | Cyclophosphamid... Fludarabine TIL infusion Interleukin-2 Ipilimumab Nivolumab | 18 Years - 70 Years | Herlev Hospital | |
| SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma | NCT04803877 | Osteosarcoma Osteosarcoma in... Osteosarcoma Re... Osteosarcoma Me... | Regorafenib 40 ... Regorafenib 20M... Nivolumab | 5 Years - | Sarcoma Alliance for Research through Collaboration | |
| Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions | NCT05327270 | Head and Neck C... | Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas | NCT03925246 | High Grade Glio... Brain Cancer | Nivolumab | 18 Years - 85 Years | Assistance Publique - Hôpitaux de Paris | |
| A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | NCT03999749 | Melanoma | Ipilimumab Nivolumab Tocilizumab | 18 Years - | NYU Langone Health | |
| Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma | NCT02626962 | Uveal Melanoma | ipilimumab Nivolumab | 18 Years - 99 Years | Grupo Español Multidisciplinar de Melanoma | |
| FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | NCT04758949 | Non-Small Cell ... | FL-101 Nivolumab Placebo | 18 Years - | Flame Biosciences | |
| Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases | NCT02621515 | Melanoma Brain Metastasi... | Nivolumab | 18 Years - | University Medical Center Groningen | |
| Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors | NCT05039073 | Recurrent Class... Refractory Clas... | Brentuximab Ved... Hematopoietic C... Nivolumab Quality-of-Life... Questionnaire A... | 12 Years - | Emory University | |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | NCT05122546 | Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re... | Cabozantinib S-... Clostridium but... Nivolumab | 18 Years - | City of Hope Medical Center | |
| Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | NCT04518046 | Clear-Cell Rena... | Sitravatinib Nivolumab Ipilimumab | 18 Years - | Mirati Therapeutics Inc. | |
| Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT03333746 | Recurrent Plasm... Refractory Plas... | Laboratory Biom... Lenalidomide Nivolumab Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma | NCT02659540 | Melanoma | Nivolumab Ipilimumab Radiotherapy | 18 Years - | Ludwig Institute for Cancer Research | |
| Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study. | NCT03784040 | Gastric Cancer | OTSGC-A24 Nivolumab Ipilimumab | 21 Years - 99 Years | National University Hospital, Singapore | |
| Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | NCT03158129 | Stage I Lung No... Stage IA Lung N... Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... | Carboplatin Cisplatin Docetaxel Ipilimumab Nivolumab Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma | NCT03418922 | Carcinoma, Hepa... | Lenvatinib Nivolumab | 20 Years - | Eisai Inc. | |
| Impact of Telemonitoring for the Management of Side Effects in Patients With Melanoma, Lung or Renal Cancer, Treated With Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy | NCT04605146 | Melanoma Lung Cancer Renal Cancer | Tele-monitoring | 18 Years - | Hospices Civils de Lyon | |
| Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads | NCT03023904 | Recurrent Non-S... Stage IV Non-Sm... | Nivolumab Laboratory Biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer | NCT03811015 | Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... | Biospecimen Col... Cisplatin Computed Tomogr... Echocardiograph... Fludeoxyglucose... Intensity-Modul... Nivolumab Patient Observa... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma | NCT04187404 | Adrenocortical ... Pheochromocytom... Paraganglioma | EO2401 Nivolumab | 18 Years - | Enterome | |
| Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial | NCT05652673 | Melanoma Stage ... Melanoma Stage ... Immunotherapy Toxicity, Drug | nivolumab | 18 Years - | Erasmus Medical Center | |
| Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | NCT05461235 | PD-1 Antibody DC-Cell NK-Cell Gastrointestina... | Pembrolizumab Nivolumab Sintilimab Toripalimab Camrelizumab Tislelizumab NK-Cell or DC-C... | 18 Years - 70 Years | China Medical University, China | |
| Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | NCT03570619 | Metastatic Cast... Metastatic Canc... Solid Tumor | Nivolumab Ipilimumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab | NCT02977052 | Malignant Melan... | Ipilimumab Nivolumab Surgery Blood for PBMCs Biopsies | 18 Years - | The Netherlands Cancer Institute | |
| A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) | NCT03071094 | Hepatocellular ... | Pexastimogene D... Nivolumab | 18 Years - | Transgene | |
| Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer | NCT03382561 | Extensive Stage... Recurrent Lung ... | Carboplatin Cisplatin Etoposide Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | NCT03921684 | Rectal Cancer | Capecitabine Radiation thera... mFOLFOX6 Nivolumab | 18 Years - | Rabin Medical Center | |
| Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition | NCT03453892 | Metastatic Canc... | Nivolumab Pembrolizumab Radiotherapy Ipilimumab | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | NCT03055013 | Metastatic Rena... Sarcomatoid Ren... Stage II Renal ... Stage III Renal... Unclassified Re... | Nephrectomy Nivolumab Patient Observa... | 18 Years - | National Cancer Institute (NCI) | |
| Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC | NCT01673867 | Non-Squamous Ce... | Nivolumab Docetaxel | 18 Years - | Bristol-Myers Squibb | |
| Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | NCT03302247 | Non Small Cell ... | Nivolumab Nivolumab+Gemci... | 18 Years - | Fox Chase Cancer Center | |
| Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | NCT03370276 | Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Head and Neck S... Squamous Cell C... Head and Neck C... | Nivolumab Cetuximab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | NCT04323046 | Glioblastoma Malignant Gliom... Recurrent Gliob... Recurrent Malig... Recurrent Grade... Grade III Gliom... | Nivolumab Quality-of-Life... Questionnaire A... | 6 Months - 25 Years | University of California, San Francisco | |
| Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | NCT03623854 | Chordoma Locally Advance... Metastatic Chor... Unresectable Ch... | Nivolumab Relatlimab | 12 Years - | Jonsson Comprehensive Cancer Center | |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | NCT03190174 | Ewing Sarcoma PEComa Epithelioid Sar... Desmoid Tumor Chordoma Non Small Cell ... Urothelial Carc... Melanoma Renal Cell Carc... Squamous Cell C... Hepatocellular ... Classical Hodgk... Colorectal Canc... MTOR Activating... | Nab-Rapamycin Nivolumab | 12 Years - | Sarcoma Oncology Research Center, LLC | |
| Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | NCT02257528 | Cervical Adenoc... Cervical Adenos... Recurrent Cervi... Stage IV Cervic... Stage IVA Cervi... Stage IVB Cervi... | Laboratory Biom... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer | NCT03351231 | Cancer | BMS-986242 Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | NCT04731467 | Solid Tumor Non Small Cell ... Pancreatic Canc... Ovarian Cancer Papillary Thyro... Melanoma Colorectal Aden... | CM-24 and Nivol... CM-24, Nivoluma... CM-24, Nivoluma... Nivolumab, Nab ... Nivolumab and N... | 18 Years - | Purple Biotech Ltd. | |
| A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) | NCT02857426 | Lymphoma | Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | NCT05180799 | Solid Tumor, Ad... NSCLC Urothelial Carc... Gastric Cancer Small Cell Lung... Hepatocellular ... Cervical Carcin... Melanoma Renal Cell Carc... Carcinoma | BA3071 Nivolumab Pembrolizumab | 18 Years - | BioAtla, Inc. | |
| Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. | NCT04749602 | Renal Cell Canc... Non-small Cell ... Pleural Effusio... | Nivolumab | 18 Years - | Kidney Cancer Research Bureau | |
| Nivolumab in Patients With Recurrent Malignant Mesothelioma | NCT02497508 | Malignant Pleur... | nivolumab | 18 Years - | The Netherlands Cancer Institute | |
| A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | NCT02860546 | Refractory Meta... | TAS-102 nivolumab | 18 Years - | Taiho Oncology, Inc. | |
| Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | NCT03829722 | Oropharynx Squa... | Nivolumab Carboplatin Paclitaxel Radiation Thera... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | NCT04150640 | Esophageal Aden... Gastric Adenoca... | Nal-IRI Oxaliplatin 5-FU Trastuzumab Pembrolizumab Nivolumab | 18 Years - | University of Wisconsin, Madison | |
| Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | NCT04507906 | NSCLC Stage IV Checkpoint Inhi... | Nivolumab Combi... | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | NCT03816345 | Autoimmune Dise... Crohn Disease Dermatomyositis Hematopoietic a... Inflammatory Bo... Malignant Solid... Multiple Sclero... Psoriasis Psoriatic Arthr... Rheumatoid Arth... Sjogren Syndrom... Systemic Lupus ... Systemic Sclero... Ulcerative Coli... | Biospecimen Col... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | NCT03707457 | Glioblastoma Glioblastoma Mu... | Nivolumab Anti-GITR Monoc... IDO1 inhibitor ... Ipilimumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | NCT02949843 | EGFR Activating... Recurrent Non-S... Stage IV Non-Sm... | Chemotherapy Immunotherapy Laboratory Biom... Nivolumab Pembrolizumab Targeted Molecu... Tyrosine Kinase... | - | Wake Forest University Health Sciences | |
| A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC | NCT02852083 | Squamous Cell L... Non-Squamous Ce... Non-Small Cell ... | Pioglitazone nivolumab Treosulfan Clarithromycin | 18 Years - | University Hospital Regensburg | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer | NCT03171025 | Bladder Cancer | Nivolumab | 18 Years - | University of Utah | |
| Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma | NCT03097939 | Nasopharyngeal ... | Ipilimumab Nivolumab | 21 Years - 80 Years | National Cancer Centre, Singapore | |
| Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS | NCT03417154 | Acute Myeloid L... Higher Risk Mye... | Nivolumab Low dose Cyclop... Low dose Cyclop... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| A Study of DF6002 Alone and in Combination With Nivolumab | NCT04423029 | Solid Tumors | DF6002 Nivolumab | 18 Years - | Dragonfly Therapeutics | |
| Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | NCT03557359 | Gliomas | Nivolumab | 18 Years - | Columbia University | |
| A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer | NCT03048136 | Non-Small Cell ... | Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | NCT03610711 | Gastroesophagea... Immune Checkpoi... | Nivolumab Relatlimab | 18 Years - 99 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
